Medical Devices

Pulsed Field Ablation Has Crossed From Adoption to Competitive Differentiation

PFA is no longer an emerging technology narrative; it is the central battleground determining EP market share. Medtronic's EPT division grew 30% in Q1 FY2027 on Affera/Sphere-9 momentum, which received an expanded CE Mark for ventricular arrhythmias in August 2026, while Boston Scientific holds approximately 65% PFA share exiting 2025 and has launched FARAPOINT to extend the ecosystem beyond atrial fibrillation. Abbott completed its planned two-product PFA portfolio with BOLT approved and Volt in limited U.S. market release, explicitly claiming no tracked competitor matches its combined PFA, RF, mapping, and LAA device stack. The EP segment is now defined by ecosystem breadth, not first-mover advantage.

GLP-1 Drugs Are Bifurcating Surgical Volume: Headwind and Tailwind Simultaneously

GLP-1 pharmaceutical adoption has split the sector into clear winners and losers by procedure type. Medtronic and Intuitive Surgical name bariatric procedure volume decline as a quantified drag embedded in forward guidance, with Intuitive explicitly incorporating GLP-1 obesity drug adoption as a named variable in its 2026 procedure growth range for the first time. ResMed presents the inverse: three-year longitudinal claims data across 1.95 million patients shows GLP-1 co-prescribed patients exhibit a greater than 6% higher CPAP resupply rate at year three, definitively converting a feared headwind into a confirmed durable tailwind for the sleep therapy franchise. The GLP-1 effect is no longer directionally ambiguous; its net impact depends entirely on which procedure a company sells.

Tariff Burden Is Now Quantified and Embedded Across the Sector's Cost Base

For the first time in a single cycle, every major large-cap medical device company has quantified tariff exposure in forward guidance rather than flagging it qualitatively. Stryker disclosed a $400 million full-year 2026 tariff impact, with an incremental $200 million versus 2025 front-loaded into H1. Baxter quantified an $80 million net impact, representing a $40 million year-over-year headwind concentrated in H1. Boston Scientific explicitly named tariff annualization as the factor capping its adjusted gross margin flat at approximately 70.6% for 2026. Becton Dickinson absorbed 170 basis points of gross margin drag in Q1 FY2026 and embedded 370 basis points of full-year EPS impact in guidance. Tariffs have moved from macro commentary to a precision engineering problem inside each company's P&L.

Structural Heart's Next Expansion Layer Is Reimbursement, Not Technology

The technology debates in TAVR and LAA closure are largely settled; the next growth lever is coverage expansion. CMS formally reopened the TAVR National Coverage Determination, with a draft expected around June 2026 and a final determination possible in Q4 2026, a catalyst Edwards Lifesciences frames as a 2027-and-beyond demand driver. Boston Scientific's CHAMPION trial readout at ACC on March 28, 2026 is the single most consequential near-term binary event in the sector, with a positive result potentially expanding the indicated WATCHMAN population from approximately 5 million to 20 million patients globally. CMS also finalized a National Coverage Determination for Medtronic's Symplicity Spyral renal denervation procedure in October 2025, removing the reimbursement gating factor that had constrained U.S. commercial scale for years. Coverage determinations, not clinical trials, now set the tempo for structural heart growth.